You are here: Industry Insights > VOCs

News List

Sorrento Exercises Exclusive Option Agreement With Texas A&M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern firstwordpharma
August 27, 2021
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has notified The Texas A&M University System ("TAMUS") of its exercise of the option to an exclusive license for the global development and commercialization of highly potent
FDA Accepts BLA, Grants Priority Review for Crizanlizumab americanpharmaceuticalreview
July 17, 2019
Novartis announced the US Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) and has granted Priority Review for its investigational sickle cell medicine crizanlizumab (SEG101).
FDA grants breakthrough therapy status to crizanlizumab pharmaceutical-technology
January 10, 2019
Novartis has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for the use of crizanlizumab (SEG101) to prevent vaso-occlusive crises (VOCs) in sickle cell disease (SCD) patients of all genotypes.....
Crizanlizumab Receives FDA Breakthrough Therapy Designation americanpharmaceuticalreview
January 09, 2019
Novartis announced the US Food and Drug Administration (FDA) has granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of .....
Novartis Announces New Crizanlizumab Data Analysis in Sickle Cell Disease americanpharmaceuticalreview
December 04, 2018
New data from a post hoc analysis of the Phase II SUSTAIN study of crizanlizumab -- a once-a-month, humanized anti-P-selectin monoclonal antibody infusion being investigated.....